FIV vaccine studies. II. Clinical findings, hematological changes and kinetics of blood lymphocyte subsets.
Five groups of cats were vaccinated with different recombinant feline immunodeficiency virus (FIV) SU vaccines expressed either in Escherichia coli or in the Baculovirus system. In Part I of this series, we described the humoral immune response and outcome of intraperitoneal FIV challenge exposure. Additionally, all cats were monitored for clinical and hematological changes and the course of blood lymphocyte subsets. These results are described in this present paper. A great increase of antibodies was found after vaccination with different recombinant FIV antigens, which did not protect the cats from intraperitoneal FIV challenge infection. This observation was paralleled by an increase of eosinophils during vaccination which was even more pronounced after challenge infection. After FIV challenge, infection lymphadenopathy, gingivitis, pharyngitis, changes in total leukocytes and neutrophils and a decrease in the CD4+:CD8+ ratio were found in cats of all groups and were considered as a sign of the FIV infection taking place, independent of vaccination. The following observations suggest that in these cats a TH2-like immune response was elicited: the high counts of eosinophils, the nature of antigen and adjuvant (aluminium hydroxide) and the high amounts of antigens used for immunization. Clearly, this type of immune response did not protect the animals from intraperitoneal FIV challenge infection.
Hofmann-Lehmann
R
R
Department of Internal Veterinary Medicine, University of Zurich, Switzerland.
Holznagel
E
E
Aubert
A
A
Bauer-Pham
K
K
Lutz
H
H
D000818:Animals; D016516:CD4-CD8 Ratio / Q000662:veterinary; D002415:Cats; D016181:Feline Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D005434:Flow Cytometry / Q000662:veterinary; D005891:Gingivitis / Q000473:pathology / Q000662:veterinary; D016089:Immunodeficiency Virus, Feline / Q000235:genetics / Q000276:immunology*; D007700:Kinetics; D008206:Lymphatic Diseases / Q000473:pathology / Q000662:veterinary; D018655:Lymphocyte Count / Q000662:veterinary; D016131:Lymphocyte Subsets / Q000276:immunology*; D008297:Male; D010612:Pharyngitis / Q000473:pathology / Q000662:veterinary; D011897:Random Allocation; D013047:Specific Pathogen-Free Organisms; D018418:Th2 Cells / Q000276:immunology; D014611:Vaccination / Q000662:veterinary; D014614:Vaccines, Synthetic / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines